These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1093 related articles for article (PubMed ID: 20124187)
1. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Blackwell KL; Burstein HJ; Storniolo AM; Rugo H; Sledge G; Koehler M; Ellis C; Casey M; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J J Clin Oncol; 2010 Mar; 28(7):1124-30. PubMed ID: 20124187 [TBL] [Abstract][Full Text] [Related]
2. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807 [TBL] [Abstract][Full Text] [Related]
3. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998 [TBL] [Abstract][Full Text] [Related]
4. [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer]. Ma F; Xu BH; Li HH; Li Q; Zhang P; Yuan P; Wang JY; Fan Y; Li Q Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):521-4. PubMed ID: 24257305 [TBL] [Abstract][Full Text] [Related]
5. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558 [TBL] [Abstract][Full Text] [Related]
6. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287 [TBL] [Abstract][Full Text] [Related]
7. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). Riemsma R; Forbes CA; Amonkar MM; Lykopoulos K; Diaz JR; Kleijnen J; Rea DW Curr Med Res Opin; 2012 Aug; 28(8):1263-79. PubMed ID: 22738819 [TBL] [Abstract][Full Text] [Related]
8. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838 [TBL] [Abstract][Full Text] [Related]
9. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ J Clin Oncol; 2018 Mar; 36(8):741-748. PubMed ID: 29244528 [TBL] [Abstract][Full Text] [Related]
10. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Crown J; Kennedy MJ; Tresca P; Marty M; Espie M; Burris HA; DeSilvio M; Lau MR; Kothari D; Koch KM; Diéras V Ann Oncol; 2013 Aug; 24(8):2005-11. PubMed ID: 23878115 [TBL] [Abstract][Full Text] [Related]
11. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. Storniolo AM; Pegram MD; Overmoyer B; Silverman P; Peacock NW; Jones SF; Loftiss J; Arya N; Koch KM; Paul E; Pandite L; Fleming RA; Lebowitz PF; Ho PT; Burris HA J Clin Oncol; 2008 Jul; 26(20):3317-23. PubMed ID: 18490651 [TBL] [Abstract][Full Text] [Related]
12. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658 [TBL] [Abstract][Full Text] [Related]
13. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. Di Leo A; Gomez HL; Aziz Z; Zvirbule Z; Bines J; Arbushites MC; Guerrera SF; Koehler M; Oliva C; Stein SH; Williams LS; Dering J; Finn RS; Press MF J Clin Oncol; 2008 Dec; 26(34):5544-52. PubMed ID: 18955454 [TBL] [Abstract][Full Text] [Related]
14. A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Takano T; Tsurutani J; Takahashi M; Yamanaka T; Sakai K; Ito Y; Fukuoka J; Kimura H; Kawabata H; Tamura K; Matsumoto K; Aogi K; Sato K; Nishio K; Nakagawa K; Saeki T Breast; 2018 Aug; 40():67-75. PubMed ID: 29698927 [TBL] [Abstract][Full Text] [Related]
15. Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer. Sotelo MJ; García-Sáenz JA; Manso L; Moreno F; Ciruelos E; Callata HR; Mendiola C; Cabezas S; Ghanem I; Díaz-Rubio E J Cancer Res Ther; 2014; 10(4):967-72. PubMed ID: 25579538 [TBL] [Abstract][Full Text] [Related]
16. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. Piccart-Gebhart M; Holmes E; Baselga J; de Azambuja E; Dueck AC; Viale G; Zujewski JA; Goldhirsch A; Armour A; Pritchard KI; McCullough AE; Dolci S; McFadden E; Holmes AP; Tonghua L; Eidtmann H; Dinh P; Di Cosimo S; Harbeck N; Tjulandin S; Im YH; Huang CS; Diéras V; Hillman DW; Wolff AC; Jackisch C; Lang I; Untch M; Smith I; Boyle F; Xu B; Gomez H; Suter T; Gelber RD; Perez EA J Clin Oncol; 2016 Apr; 34(10):1034-42. PubMed ID: 26598744 [TBL] [Abstract][Full Text] [Related]
19. Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial. Thallinger C; Lang I; Kuhar CG; Bartsch R; Singer CF; Petruzelka L; Melichar B; Knittelfelder R; Brodowicz T; Zielinski C BMC Cancer; 2016 Feb; 16():121. PubMed ID: 26887956 [TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). Lin NU; Guo H; Yap JT; Mayer IA; Falkson CI; Hobday TJ; Dees EC; Richardson AL; Nanda R; Rimawi MF; Ryabin N; Najita JS; Barry WT; Arteaga CL; Wolff AC; Krop IE; Winer EP; Van den Abbeele AD J Clin Oncol; 2015 Aug; 33(24):2623-31. PubMed ID: 26169615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]